Arkolith/Insider Trading/URGN/Form 4

Schoenberg Mark

Chief Medical OfficerUroGen Pharma Ltd. (URGN) · full profile →Form 4 · filed Feb 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
3 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2026Option exercise(M)3K——142K
Jan 31, 2026Option exercise(M)3K——146K
Jan 31, 2026Option exercise(M)7K——152K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2026Option exercise(M)3K—$03K
Jan 31, 2026Grant(A)20K—$020K
Jan 31, 2026Option exercise(M)3K—$00
Jan 31, 2026Option exercise(M)7K—$013K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-002843) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML